Compare Alliant Energy Corporation (LNT) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alliant Energy Corporation vs 10X Genomics Inc — how do they compare? Alliant Energy Corporation trades at $73.98 (market cap $19.10B), while 10X Genomics Inc trades at $47.2 (market cap $5.48B). The key difference: Alliant Energy Corporation is far larger — about 3.5× 10X Genomics Inc's market cap, and Alliant Energy Corporation pays a 2.89% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| LNT | TXG | |
|---|---|---|
Market Cap | $19.10B | $5.48B |
Sector | Utilities | Health |
52-Week High | $78.03 | $45.80 |
52-Week Low | $63.62 | $11.34 |
Enterprise Value | $30.83B | $5.02B |
Dividend Yield | 2.89% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Alliant Energy (LNT) trades at $73.11, down 2.29% on the day, with a bullish technical outlook and strong analyst support. The stock shows steady revenue growth, improving net income margins to 18.58% in 2025, and consistent dividend payments. Recent news highlights its $13.4 billion clean energy investment plan targeting 5-7% annual earnings growth, driven by data center demand and grid modernization initiatives.
LNT presents a favorable risk-reward profile with a consensus price target of $78.50, offering 7.4% upside. Key risks include rising debt levels and execution of capital-intensive projects. The bullish analyst consensus (52% Buy) and institutional confidence support long-term growth, though investors should monitor interest rate sensitivity and regulatory developments.
TXG trades at $47.20, up 7.91% on the day, with a bullish technical signal from moving averages. The company reported Q1 2026 revenue that beat estimates, and net losses have narrowed significantly from -$255M in 2023 to -$44M in 2025. Operating cash flow turned strongly positive at $136M in 2025. Recent developments include the acquisition of Proteintech Genomics and a collaboration with Cleveland Clinic on bladder cancer diagnostics.
The outlook is mixed; improving fundamentals and strategic expansions support growth, but persistent net losses and a high EV/EBITDA of 133.91 pose valuation risks. Analyst consensus is divided with a $39.14 price target below the current price, indicating caution despite a majority buy/hold ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alliant Energy Corporation
Alliant Energy is the parent of two regulated utilities, Interstate Power and Light and Wisconsin Power and Light, serving nearly 1 million electricity and natural gas customers and approximately 420,000 natural gas-only customers. Both subsidiaries engage in the generation and distribution of electricity and the distribution and transportation of natural gas. Alliant also owns a 16% interest in American Transmission Co.
Read more on LNT →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
